Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pfizer Inc. filings document the financial, governance, capital-structure, and material-event disclosures of a global biopharmaceutical company. The company's 8-K reports include quarterly operating results, financial guidance updates, Regulation FD disclosures, clinical or regulatory disclosure categories, material agreements, and other corporate events tied to its medicines, vaccines, pipeline, and commercial organization.
Pfizer's proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, shareholder voting results, and equity-plan governance. Its capital markets filings and 8-K exhibits also disclose common stock, NYSE-listed notes, shelf registration activity, public debt offerings, note maturities, and related capital-structure terms.
LITTMAN DAN R. reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Dan R. Littman received an award of 7,686.539 Phantom Stock Units on deferred compensation terms. Each unit represents one phantom share of Pfizer common stock and is tied to a reference price of $26.67 per unit.
After this grant, Littman holds a total of 74,533.568 Phantom Stock Units. The units represent deferred director compensation under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and will be settled in cash or common stock, at his election, after he retires from the Board.
BLAYLOCK RONALD E reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Ronald E. Blaylock received a grant of 7,686.539 Phantom Stock Units linked to Pfizer common stock. The units, valued using a reference price of $26.67 per unit, increase his total phantom stock holdings to 84,012.660 units. Each unit represents one phantom share and was granted under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. This award represents deferred director compensation that will be settled in cash or common stock, at his election, after he retires from the Board.
Buckley Mortimer J reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Mortimer J. Buckley received a grant of phantom stock units as part of his deferred compensation. On this Form 4, he was awarded 7,686.539 phantom stock units tied to Pfizer common stock, bringing his total phantom units to 24,391.124 held directly.
Each unit represents one phantom share of common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units reflect deferred director compensation and will be settled in cash or Pfizer common stock, at the director’s election, after he retires from the Board of Directors.
Desmond-Hellmann Susan reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Susan Desmond-Hellmann received a grant of phantom stock units as part of her deferred board compensation. On this Form 4, she was awarded 7,686.539 phantom stock units, each linked to one share of Pfizer common stock. Following the award, she holds 45,635.605 phantom stock units in total. These units are granted under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and will be settled in cash or common stock, at her election, after she retires from the board.
Echevarria Joseph reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Joseph Echevarria received a grant of 7,686.539 Phantom Stock Units tied to common stock. The units were awarded as director compensation under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and bring his reported phantom unit balance to 161,084.684. Each unit represents one phantom share and will be settled in cash or common stock, at his election, after he retires from the board.
Pfizer Inc. director Shantanu Narayen received a grant of 7,686.539 Phantom Stock Units on common stock-equivalent terms. The award was made at a reference value of $26.67 per unit and is classified as a grant or award acquisition rather than an open-market purchase.
Following this grant, Narayen holds a total of 195,611.680 Phantom Stock Units directly. Each unit represents one phantom share of Pfizer common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units reflect deferred director compensation that will be settled in cash or common stock, at Narayen’s election, after his retirement from the Board.
PFIZER INC Executive Vice President Dennis P. Hancock filed an amended Form 3 to correct his initial insider holdings report. The amendment adds 1,940 shares of common stock held indirectly through the Pfizer Savings Plan under a Rule 16b-3 plan that were previously omitted.
Quincey James reported acquisition or exercise transactions in this Form 4 filing.
PFIZER INC director James Quincey reported a compensation grant of phantom stock units tied to Pfizer common stock. He received 7,686.539 phantom stock units on the reported date at a reference value of $26.67 per unit.
Each unit represents one phantom share of common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units reflect deferred director compensation and will be settled in cash or common stock, at Quincey’s election, after he retires from the Board. Following this award, his balance under this plan increased to 85,004.077 phantom stock units.
SMITH JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director James C. Smith received a grant of 7,686.539 Phantom Stock Units as deferred compensation. Each unit represents one phantom share of Pfizer common stock and was valued at $26.67 per unit for this award. After this grant, Smith holds 178,111.302 Phantom Stock Units directly. The units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and represent deferred director compensation. According to the terms, these units will be settled in cash or Pfizer common stock, at Smith’s election, after he retires from the Board of Directors.
Taraporevala Cyrus reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Cyrus Taraporevala received a grant of 7,686.539 Phantom Stock Units tied to Pfizer common stock. Each unit represents one phantom share of common stock and was valued at $26.67 per unit for this grant.
The award was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors as deferred director compensation. These units will be settled in cash or common stock, at the director’s election, after retirement from the Board of Directors. Following this grant, Taraporevala holds a total of 34,826.086 Phantom Stock Units directly.